About Albireo Pharma (NASDAQ:ALBO)
Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company's BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.
Industry, Sector and Symbol
Industry Drug Manufacturers - Other
Trailing P/E Ratio15.5806451612903
Forward P/E Ratio-9.89
Sales & Book Value
Annual Sales$11.36 million
Price / Sales32.29
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions
What is Albireo Pharma's stock symbol?
Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."
How were Albireo Pharma's earnings last quarter?
Albireo Pharma, Inc. (NASDAQ:ALBO) posted its earnings results on Monday, August, 21st. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.84) by $0.02. View Albireo Pharma's Earnings History.
Where is Albireo Pharma's stock going? Where will Albireo Pharma's stock price be in 2018?
4 Wall Street analysts have issued 12-month price objectives for Albireo Pharma's stock. Their forecasts range from $50.00 to $92.00. On average, they expect Albireo Pharma's share price to reach $66.67 in the next year. View Analyst Ratings for Albireo Pharma.
What are Wall Street analysts saying about Albireo Pharma stock?
Here are some recent quotes from research analysts about Albireo Pharma stock:
- 1. According to Zacks Investment Research, "Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. " (1/24/2018)
- 2. Wedbush analysts commented, "Zynerba updated its plans to focus development on rare and near-rare neurological and psychiatric disorders." (1/3/2018)
- 3. Cowen Inc analysts commented, "Albireo reported 3Q earnings today and provided a brief summary of recent progress." (11/17/2017)
- 4. Needham & Company LLC analysts commented, "Albireo hosted a KOL meeting yesterday in NYC to discuss Progressive Familial Intrahepatic Cholestasis (PFIC) and provide an update on A4250 clinical program. E. Sturm, investigator in A4250 Phase 2 trial in pediatric cholestasis, highlighted unmet need in PFIC and other rare pediatric cholestasis indications. Biliary diversion surgery is effective option for reducing bile acids in serum, but has 20-40% failure rate. Dr. Sturm is eager for other options and views AB4250 Phase 2 safety and efficacy profile as compelling. Initiation of Phase 3 trial in PFIC1 and PFIC2 patients expected around YE17." (10/26/2017)
Who are some of Albireo Pharma's key competitors?
Some companies that are related to Albireo Pharma include Inflarx (IFRX), La Jolla Pharmaceutical (LJPC), Jounce Therapeutics (JNCE), Rhythm Pharmaceuticals (RYTM), Urogen Pharma (URGN), AC Immune (ACIU), Kura Oncology (KURA), Reata Pharmaceuticals (RETA), Rocket Pharmaceuticals (RCKT), Akebia Therapeutics (AKBA), NuCana (NCNA), Tabula Rasa HealthCare (TRHC), STAAR Surgical (STAA), TiGenix - American Depositary Shares (TIG), Entellus Medical (ENTL), AngioDynamics (ANGO), Aclaris Therapeutics (ACRS) and Dicerna Pharmaceuticals (DRNA).
Who owns Albireo Pharma stock?
Albireo Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (12.17%), Artal Group S.A. (2.76%), Sectoral Asset Management Inc (2.24%), Renaissance Technologies LLC (1.11%), Millennium Management LLC (0.43%) and Sphera Funds Management LTD. (0.33%). Company insiders that own Albireo Pharma stock include Life Sciences Maste Perceptive, Phase4 Partners Ltd and Plc Astrazeneca. View Institutional Ownership Trends for Albireo Pharma.
Who sold Albireo Pharma stock? Who is selling Albireo Pharma stock?
Albireo Pharma's stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Renaissance Technologies LLC and Hartwell J M Limited Partnership. Company insiders that have sold Albireo Pharma company stock in the last year include Phase4 Partners Ltd and Plc Astrazeneca. View Insider Buying and Selling for Albireo Pharma.
Who bought Albireo Pharma stock? Who is buying Albireo Pharma stock?
Albireo Pharma's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Artal Group S.A., Sectoral Asset Management Inc, Millennium Management LLC, Ardsley Advisory Partners, Bank of New York Mellon Corp and Wells Fargo & Company MN. View Insider Buying and Selling for Albireo Pharma.
How do I buy Albireo Pharma stock?
Shares of Albireo Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Albireo Pharma's stock price today?
One share of Albireo Pharma stock can currently be purchased for approximately $33.81.
How big of a company is Albireo Pharma?
Albireo Pharma has a market capitalization of $368.45 million and generates $11.36 million in revenue each year. The biopharmaceutical company earns $-4,030,000.00 in net income (profit) each year or $2.17 on an earnings per share basis. Albireo Pharma employs 12 workers across the globe.
How can I contact Albireo Pharma?
Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]
MarketBeat Community Rating for Albireo Pharma (ALBO)MarketBeat's community ratings are surveys of what our community members think about Albireo Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Albireo Pharma (NASDAQ:ALBO) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$66.67||$61.67||$61.67||$35.00|
|Price Target Upside: ||94.36% upside||86.87% upside||137.27% upside||63.32% upside|
Albireo Pharma (NASDAQ:ALBO) Consensus Price Target History
Albireo Pharma (NASDAQ:ALBO) Analyst Ratings History
(Data available from 2/22/2016 forward)
Albireo Pharma (NASDAQ:ALBO) Earnings History and Estimates Chart
Albireo Pharma (NASDAQ ALBO) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Albireo Pharma (NASDAQ:ALBO) Earnings Estimates
2018 EPS Consensus Estimate: ($3.36)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Albireo Pharma (NASDAQ:ALBO)
No dividend announcements for this company have been tracked by MarketBeat.com
Albireo Pharma (NASDAQ ALBO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 22.30%
Institutional Ownership Percentage: 26.78%
Albireo Pharma (NASDAQ ALBO) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/30/2018||Phase4 Partners Ltd||Major Shareholder||Sell||100,000||$34.44||$3,444,000.00|| |
|1/25/2018||Life Sciences Maste Perceptive||Major Shareholder||Buy||275,000||$33.00||$9,075,000.00|| |
|12/1/2017||Plc Astrazeneca||Major Shareholder||Sell||500,000||$21.40||$10,700,000.00|| |
|12/20/2013||Brian Jg Pereira||Director||Sell||4,734||$2.26||$10,698.84|| |
Albireo Pharma (NASDAQ ALBO) News Headlines
|Albireo Pharma (ALBO) and Alexza Pharmaceuticals (ALXA) Critical Review|
www.americanbankingnews.com - February 20 at 9:08 PM
|Head-To-Head Contrast: Albireo Pharma (ALBO) versus Alexza Pharmaceuticals (ALXA)|
www.americanbankingnews.com - February 17 at 7:32 PM
|Analyzing Alexza Pharmaceuticals (ALXA) and Albireo Pharma (ALBO)|
www.americanbankingnews.com - February 17 at 1:16 AM
|Reviewing Albireo Pharma (ALBO) and Alexza Pharmaceuticals (ALXA)|
www.americanbankingnews.com - February 15 at 11:12 PM
|Critical Comparison: Alexza Pharmaceuticals (ALXA) and Albireo Pharma (ALBO)|
www.americanbankingnews.com - February 8 at 11:20 AM
|Albireo Pharma, Inc. (ALBO) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - February 7 at 3:24 AM
|Needham & Company LLC Raises Albireo Pharma (ALBO) Price Target to $50.00|
www.americanbankingnews.com - February 2 at 2:25 PM
|Albireo Pharma, Inc. (ALBO) Major Shareholder Sells $3,444,000.00 in Stock|
www.americanbankingnews.com - February 1 at 6:10 PM
|Albireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares|
finance.yahoo.com - January 29 at 4:28 PM
|Albireo Pharma, Inc. (ALBO) Major Shareholder Life Sciences Maste Perceptive Buys 275,000 Shares|
www.americanbankingnews.com - January 25 at 9:12 PM
|Albireo Prices $65.0 Million Public Offering of Common Stock|
finance.yahoo.com - January 25 at 9:05 AM
|Zacks: Analysts Anticipate Albireo Pharma, Inc. (ALBO) to Post -$0.78 EPS|
www.americanbankingnews.com - January 24 at 11:10 PM
|Albireo Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - January 24 at 4:47 PM
|Albireo Pharma (ALBO) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - January 24 at 4:06 PM
|Albireo Pharma's (ALBO) Buy Rating Reaffirmed at Wedbush|
www.americanbankingnews.com - January 19 at 8:44 PM
|Albireo to Receive More than $55 Million(1) in Nondilutive Cash Payments|
finance.yahoo.com - January 19 at 12:19 PM
|Albireo Pharma (ALBO) Downgraded to Hold at Zacks Investment Research|
www.americanbankingnews.com - January 17 at 4:42 PM
|Albireo Pharma (ALBO) Rating Increased to Buy at Zacks Investment Research|
www.americanbankingnews.com - January 16 at 4:36 PM
|Albireo Pharma, Inc. (ALBO) Given Consensus Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - January 13 at 4:01 AM
|Albireo Pharma (ALBO) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - January 11 at 4:52 PM
|Albireo Pharma (ALBO) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - January 8 at 9:26 PM
|Wedbush Equities Analysts Increase Earnings Estimates for Albireo Pharma, Inc. (ALBO)|
www.americanbankingnews.com - January 8 at 7:12 AM
|William Blair Comments on Albireo Pharma, Inc.'s Q1 2018 Earnings (ALBO)|
www.americanbankingnews.com - January 8 at 6:02 AM
|Zacks: Brokerages Expect Albireo Pharma, Inc. (ALBO) Will Post Earnings of -$0.78 Per Share|
www.americanbankingnews.com - January 7 at 7:24 PM
|Albireo Pharma, Inc. (ALBO) to Post FY2022 Earnings of $7.44 Per Share, Wedbush Forecasts|
www.americanbankingnews.com - January 5 at 8:24 PM
|Wedbush Reaffirms Buy Rating for Albireo Pharma (ALBO)|
www.americanbankingnews.com - January 3 at 9:22 PM
|Albireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in Japan|
finance.yahoo.com - January 3 at 9:55 AM
|Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)|
finance.yahoo.com - December 29 at 4:11 PM
|Albireo Pharma, Inc. (ALBO) Expected to Announce Earnings of -$0.78 Per Share|
www.americanbankingnews.com - December 22 at 1:22 PM
|Biodel Inc. (ALBO) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - December 19 at 3:36 AM
|Biodel Inc. to Post FY2017 Earnings of ($3.33) Per Share, Wedbush Forecasts (ALBO)|
www.americanbankingnews.com - December 11 at 2:10 AM
|Critical Analysis: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)|
www.americanbankingnews.com - December 7 at 3:32 AM
|Biodel Inc. (ALBO) Major Shareholder Sells $10,700,000.00 in Stock|
www.americanbankingnews.com - December 5 at 5:36 PM
| Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.78 EPS|
www.americanbankingnews.com - December 4 at 3:14 PM
|RegeneRx Biopharmaceuticals (RGRX) & Biodel (ALBO) Critical Comparison|
www.americanbankingnews.com - December 4 at 1:28 PM
|Analyzing RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)|
www.americanbankingnews.com - December 1 at 5:40 AM
|Financial Comparison: Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)|
www.americanbankingnews.com - November 27 at 12:15 PM
|Comparing Biodel (ALBO) & RegeneRx Biopharmaceuticals (RGRX)|
www.americanbankingnews.com - November 26 at 5:10 AM
|Analyzing Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)|
www.americanbankingnews.com - November 25 at 1:16 PM
|Biodel Inc. (ALBO) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - November 24 at 3:56 AM
|Critical Contrast: RegeneRx Biopharmaceuticals (RGRX) & Biodel (ALBO)|
www.americanbankingnews.com - November 19 at 9:28 AM
|Biodel Inc. Expected to Earn FY2017 Earnings of ($3.40) Per Share (ALBO)|
www.americanbankingnews.com - November 17 at 9:44 PM
|Biodel Inc. (ALBO) Stock Rating Reaffirmed by Cowen and Company|
www.americanbankingnews.com - November 17 at 7:58 PM
|Zacks: Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.82 Earnings Per Share|
www.americanbankingnews.com - November 16 at 5:18 AM
|Biodel Inc. (ALBO) Coverage Initiated by Analysts at Roth Capital|
www.americanbankingnews.com - November 15 at 11:41 AM
|Albireo Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 14 at 4:13 PM
|Zacks Investment Research Lowers Biodel Inc. (ALBO) to Hold|
www.americanbankingnews.com - November 13 at 8:30 PM
|Albireo to Present at the Jefferies 2017 London Healthcare Conference|
finance.yahoo.com - November 9 at 4:44 PM
|Biodel Inc. (ALBO) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - October 30 at 1:40 AM
|Biodel Inc. (ALBO) Receives "Buy" Rating from Needham & Company LLC|
www.americanbankingnews.com - October 26 at 11:58 PM
Albireo Pharma (NASDAQ:ALBO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Albireo Pharma (NASDAQ:ALBO) Income Statement, Balance Sheet and Cash Flow Statement
Albireo Pharma (NASDAQ ALBO) Stock Chart for Thursday, February, 22, 2018